

Neuland Laboratories Limited

11th Floor (5th Office Level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad - 500033, Telangana, India.

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

May 11, 2024

To **BSE Limited** Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001

The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai - 400 001

Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Copies of newspaper advertisement regarding financial results of the Company for the quarter and year ended March 31, 2024

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please find enclosed copies of newspaper advertisement regarding the Financial Results of the Company for the quarter and year ended March 31, 2024, as published in Financial Express and Andhra Prabha on May 11, 2024.

This is for your information and records.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary

Encl: As above

NEULAND LABORATORIES LIMITED

(CIN: L85195TG1984PLC004393)

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033



EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

(Amount in lakhs of ₹, unless otherwise stated)

SI. No.		Quarter Ended 31.03.2024 (Audited)	Quarter Ended 31.12.2023 (Unaudited)	Quarter Ended 31.03.2023 (Audited)	Year Ended 31.03.2024 (Audited)	Year Ended 31.03.2023 (Audited)
48.6	Total Income	39,036.67	39,492.89	41,513.68	157,112.48	120,094.62
2	Net profit before tax	9,220.20	10,448,10	11,016.36	40,143.65	21,574.64
3	Net profit after tax	6,756.19	8,139.02	8,454.39	30,007.89	16,351.76
4	Total comprehensive income	6,845.02	8,147.27	8,244.42	30,143.82	16,001.06
2007	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05	1,290.05
	Other equity (excluding revaluation reserves) as shown in the audited balance sheet		(8)	*	126,896.54	98,035.71
2011	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)					
	(a) Basic	52.66	63.44	65.90	233.89	127.45
	(b) Diluted	52.66	63.44	65.90	233.89	127.45

Note 1: The financial results for the quarter and year ended March 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 10, 2024.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 31.03.2024 (Audited)	Quarter Ended 31,12,2023 (Unaudited)	Quarter Ended 31.03,2023 (Audited)	Year Ended 31.03.2024 (Audited)	Year Ended 31.03.2023 (Audited)
Total Income	39,036.67	39,492.89	41,513.67	157,112.48	120,094.61
Net profit before tax	9,208.09	10,378.00	11,002.26	40,076.92	21,521.29
Net profit after tax	6,760.72	8,070.12	8,451.03	29,959.62	16,311.92

Note 3: The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

For and on behalf of the Board of Directors

Dr. D.R.Rao Executive Chairman (DIN 00107737)

Place: Hyderabad Date: May 10, 2024 (CIN: L85195TG1984PLC004393)

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033



EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

(Amount in takhs of ₹, unless otherwise stated)

Sl. No.		Quarter Ended 31.03.2024 (Audited)	Quarter Ended 31.12.2023 (Unaudited)	Quarter Ended 31.03.2023 (Audited)	Year Ended 31.03.2024 (Audited)	Year Ended 31.03.2023 (Audited)
	Total Income Net profit before tax Net profit after tax	39,036.67 9,220.20 6,756.19	39,492.89 10,448.10 8,139.02	41,513.68 11,016.36 8,454.39	157,112.48 40,143.65 30,007,89	120,094.62 21,574.64 16,351.76
4	Total comprehensive income Paid-up Equity Share Capital	6,845.02 1,290.05	8,147.27 1,290.05	8,244.42 1,290.05	30,143.82 1,290.05	16,001.06
6	(Face value - ₹10 each) Other equity (excluding revaluation reserves) as shown in the audited balance sheet	*	÷		126,896.54	98,035.71
	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)	52.66	63.44	65.90	233.89	127.45
	(a) Basic (b) Diluted	52.66	63.44	65.90	233.89	127.45

Note 1: The financial results for the quarter and year ended March 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 10, 2024.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 31.03.2024 (Audited)	Quarter Ended 31.12.2023 (Unaudited)	Quarter Ended 31.03.2023 (Audited)	Year Ended 31.03.2024 (Audited)	Year Ended 31.03.2023 (Audited)
Total Income	39,036.67	39,492.89	41,513.67	157,112.48	120,094.61
Net profit before tax	9,208.09	10,378.00	11,002.26	40,076.92	21,521.29
Net profit after tax	6,760.72	8,070.12	8,451.03	29,959.62	16,311.92

Note 3: The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites, www.neulandlabs.com and www.bseindia.com and on the Company's website www.neulandlabs.com

For and on behalf of the Board of Directors

Dr. D.R.Rao Executive Chairman

(DIN 00107737

Place: Hyderabad Date: May 10, 2024

1